Clinicopathological features and prognosis of breast cancer and lung cancer double primary cancer
10.3760/cma.j.cn115396-20241217-00393
- VernacularTitle:乳腺癌肺癌双原发癌的临床病理特征及预后分析
- Author:
Yang WANG
1
;
Liu YANG
;
Zhicheng GE
Author Information
1. 首都医科大学附属北京友谊医院普外科，北京 100050
- Keywords:
Breast cancer;
Lung cancer;
Neoplasms, second primary;
Pathology, clinical;
Prognosis
- From:
International Journal of Surgery
2025;52(2):85-93
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinicopathological features and prognosis of double primary cancer of breast cancer and lung cancer.Methods:A total of 40 patients with breast cancer and lung cancer admitted to Beijing Friendship Hospital, Capital Medical University from December 2015 to December 2023 were retrospectively selected, and the clinicopathological characteristics and prognosis of patients with double primary cancer included in the study were analyzed. The count data were expressed as the number of cases and percentage, Chi-test was used for inter-group comparison or Fisher exact probability method was used for single frequency < 5, rank sum test was used for inter-group comparison of two-sample levels, and Kruskal-Walllis H test was used for inter-group comparison of three-sample levels. The survival rate and survival were analyzed by Kaplan-Meier method, and the survival curve was compared by Log-rank method. Results:Among the 40 patients, 50% were patients with simultaneous and metachronous double primary cancer. And there were statistically significant differences between the two groups in the number of lymph node metastases and whether to receive endocrine therapy ( P=0.025, 0.028). There were 32 patients firstly appear breast cancer, while 8 patients firstly appear lung cancer. And there were statistically significant differences in the body mass index and TNM stage of breast cancer between the two groups ( P=0.004, 0.015). The proportion of progesterone receptor positive patients with human epidermal growth factor receptor 2 low-expression in breast cancer was significantly higher than that in patients with HER2 non-expression and HER2 overexpression ( P=0.023). 92.5% of patients had lung adenocarcinoma, and 77.5% of patients were clinical stage I of lung cancer, and the overall survival of patients who received adjuvant therapy after lung cancer surgery was significantly lower than that of patients without adjuvant therapy, the difference was statistically significant ( P<0.001). Conclusion:The prognosis of patients receiving adjuvant therapy after lung cancer surgery is poor, and regular follow-up after breast cancer surgery is helpful for early detection and early treatment of lung cancer.
